Research Output per year
Fingerprint Dive into the research topics where Cancer Institute of New Jersey (CINJ), Pediatric Hematology/Oncology is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Medicine & Life Sciences
Methotrexate
Medicine & Life Sciences
Pediatrics
Medicine & Life Sciences
Hodgkin Disease
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Peter Cole
- Cancer Institute of New Jersey (CINJ), Pediatric Hematology/Oncology - PROF-TE-DIV CHIEF
- Clinical Investigations and Precision Therapeutics Program, CINJ - FULL MEMBER
Person
Richard Drachtman
- Cancer Institute of New Jersey (CINJ), Pediatric Hematology/Oncology - PROF-CLIN-DIV CHIEF
- Clinical Investigations and Precision Therapeutics Program, CINJ - ASSOCIATE MEMBER
Person
Research Output 1991 2019
1
Citation
(Scopus)
Association of Combined Modality Therapy vs Chemotherapy Alone with Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma
Jhawar, S. R., Rivera-Núñez, Z., Drachtman, R., Cole, P., Hoppe, B. S. & Parikh, R., May 1 2019, In : JAMA Oncology. 5, 5, p. 689-695 7 p.Research output: Contribution to journal › Article
Combined Modality Therapy
Hodgkin Disease
Pediatrics
Drug Therapy
Survival
Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort
Ladas, E. J., Orjuela, M., Stevenson, K., Cole, P., Lin, M., Athale, U. H., Clavell, L. A., Leclerc, J. M., Laverdiere, C., Michon, B., Schorin, M. A., Welch, J. G., Asselin, B. L., Sallan, S. E., Silverman, L. B. & Kelly, K. M., Jan 1 2019, (Accepted/In press) In : Clinical Nutrition.Research output: Contribution to journal › Article
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Nutrition Surveys
Pediatrics
Therapeutics
Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly, K. M., Cole, P., Pei, Q., Bush, R., Roberts, K. B., Hodgson, D. C., McCarten, K. M., Cho, S. Y. & Schwartz, C., Jan 1 2019, In : British Journal of Haematology.Research output: Contribution to journal › Article
Hodgkin Disease
Positron-Emission Tomography
Confidence Intervals
Recurrence
Radiotherapy